Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients

Leuk Lymphoma. 2019 May;60(5):1224-1233. doi: 10.1080/10428194.2018.1519810.

Abstract

Since 2000, an adapted LMB 96 protocol was implemented at the Children-Welfare-Teaching-Hospital in Baghdad for the treatment of childhood B-cell non-Hodgkin lymphoma. The first experience (2000-2005) demonstrated efficacy and feasibility of this protocol in Iraq. In 2006, further adjustments were made in an attempt to reduce therapy-related toxicities. The outcome of the second cohort of 190 children (2006-2010) and the comparison with the previous study are hereby reported. Out of the 180 treated patients, 120 achieved a complete response; during treatment 51 died and 9 abandoned. The 60-month overall survival (OS) and event-free survival (EFS) were 64.7 and 56.3%, respectively. No differences were observed in the 24-month OS and EFS between the 2000-2005 and 2006-2010 cohorts (66.3% vs. 65.1%; p = .89 and 53.3% vs. 57.3%; p = .28, respectively). Therapeutic group-B in the second cohort showed better outcome, although not significant, compared to the first one (EFS 62.9% vs. 53.8%; p = .088). Therapy-related mortality remained high.

Keywords: B-cell non-Hodgkin lymphoma; children; low-income country.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asparaginase / adverse effects
  • Asparaginase / therapeutic use
  • Biopsy
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Cytarabine / adverse effects
  • Cytarabine / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Hydrocortisone / adverse effects
  • Hydrocortisone / therapeutic use
  • Infant
  • Iraq
  • Leucovorin / adverse effects
  • Leucovorin / therapeutic use
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / mortality
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use
  • Methylprednisolone / adverse effects
  • Methylprednisolone / therapeutic use
  • Neoplasm Staging
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Prognosis
  • Remission Induction
  • Survival Rate
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Cytarabine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Asparaginase
  • Leucovorin
  • Prednisone
  • Hydrocortisone
  • Methylprednisolone
  • Methotrexate

Supplementary concepts

  • COPAD protocol
  • COPADEM protocol